Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation

Annals of Internal Medicine

Volumn 128, Issue 10, 1998, Pages 810-816

  Féray, Cyrille ^a   Gigou, Michèle ^a   Samuel, Didier ^a   Ducot, Béatrice ^b   Maisonneuve, Pascale ^c   Reynès, Michel ^a   Bismuth, Alain ^a   Bismuth, Henri ^a  

^a HÔPITAL PAUL BROUSSE   (France)

^b BICÊTRE HOSPITAL   (France)

^c Centre de Transfusion Sanguine   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; HEPATITIS B ANTIBODY; HEPATITIS C ANTIBODY; MONOCLONAL ANTIBODY; OKT 3; POLYCLONAL ANTIBODY; TACROLIMUS; THYMOCYTE ANTIBODY;

ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GRAFT REJECTION; HEPATITIS C; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL;

EID: 0032524752     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-128-10-199805150-00003     Document Type: Article

References (23)

1. Wright TL, Donegan E, Hsu H, Ferrell L, Lake JR, Kim M, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology. 1992;103:317-22.
2. Féray C, Gigou M, Samuel D, Paradis V, Wilber J, David MF, et al. The course of hepatitis C infection after liver transplantation. Hepatology. 1994; 20:1137-43.
3. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993;329:1842-7.
4. Farci P, Alter HJ, Govindarajan S, Wong D, Engle R, Lesniewski RR, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science. 1992;258:135-40.
5. Yap PL, McOmish F, Webster AD, Hammarstrom L, Smith CI, Bjorkander J, et al. Hepatitis C virus transmission by intravenous immunoglobulin. J Hepatol. 1994;21:455-60.
6. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med. 1994;331:1607-11.
7. Lefrere J, Mariotti M, Trépo C, Li J, Lunel F, Frangeul L, et al. Testing for HCV-RNA in commercial intravenous immunoglobulins [Letter]. Lancet. 1993;341:835.
8. Samuel D, Bismuth A, Mathieu D, Arulnaden JL, Reynes M, Benhamou JP, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet. 1991;337:813-5.
9. Randomised trial comparing tacrolimus (FK506) to cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet. 1994;344:423-8.
10. Farges O, Ericzon BG, Bresson-Hadni S, Lynch SV, Hockerstedt K, Houssin D, et al. Randomized trial of OKT3-based versus cydosporine-tased immunoprophylaxis after liver transplantation. Long-term results of a European and Australian multicenter study. Transplantation. 1994;58:891-8.
11. Scotto J, Hadchouel M, Hery C, Yvart J, Tiollais P, Bréchot C. Detection of hepatitis B virus DNA in serum by a simple spot hybridization technique: comparison with results for other viral markers. Hepatology. 1983;3:279-84.
12. Féray C, Samuel D, Thiers V, Gigou M, Pichon F, Bismuth A, et al. Reinfection of liver graft by hepatitis C virus after liver transplantation. J Clin Invest. 1992;89:1361-5.
13. Kwok S, Higushi R. Avoiding false positives with PCR. Nature. 1989;339: 237-8.
14. Knodell R, Conrad ME, Ginsberg AL, Bell CJ. Efficacy of prophylactic gamma-globulin in preventing non-A, non-B post-transfusion hepatitis. Lancet. 1976;1:557-61.
15. Sanchez-Quijano A, Pineda JA, Lissen E, Leal M, Diaz-Torres MA, De Pesquera F, et al. Prevention of post-transfusion non-A, non-B hepatitis by non-specific immunoglobulin in heart surgery patients. Lancet. 1988;1:1245-9.
16. Choo QL, Kuo G, Ralston R, Weiner A, Chien D, Nest GV, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA. 1994;91:1294-8.
17. Shimizu YK, Hijikata M, Iwamoto A, Alter HJ, Purcell RH, Yoshikura H. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol. 1994;68:1494-500.
18. Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, Engle R, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA. 1994;91:7792-6.
19. Krawczynski K, Alter MJ, Tankersley DL, Beach M, Robertson BH, Lambert S, et al. Effect of immune globulin on the prevention of experimental hepatitis C infection. J Infect Dis. 1996;173:822-8.
20. Alberti A, Pontisso P, Chemello L, Fattovitch G, Benvegnu L, Belussi F, et al. The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. J Hepatol. 1995;22:38-41.
21. Féray C, Zignego AL, Samuel D, Bismuth A, Tiollais P, Bismuth H, et al. Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplantation model. Transplantation. 1990;49:1155-8.
22. Farges O, Saliba F, Farhamant H, Samuel D, Bismuth A. Reynès M, et al. Incidence of reinfection and infection after liver transplantation as a function of the primary disease: possible influence of alcohol and polyclonal immunoglobulins. Hepatology. 1996;5:569-72.
23. Nowak T, Gregersen J, Klockmann U, Cummins LB, Hilfenhaus J. Virus safety of human immunoglobulins: efficient inactivation of hepatitis C and other human pathogenic viruses by the manufacturing procedure. J Med Virol. 1992;36:209-16.